PregnancyNCT01662596
Detection of Risk Factors for Fetal Anomalies in a Rural Hospital Population
An observational study of Pregnancy and Pregnancy Complications, run by Hillel Yaffe Medical Center at 1 site in Israel.
Trial summary
The purpose of the study is to estimate the rate of risk factors for appearance of disease or fetal malformations in a population who turn to hospital "Hillel Yaffe" and examine whether there is a difference in the rate of early testing for diseases or birth defects in the fetus. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Pregnancy, Pregnancy Complications
- How many people
- 320 participants
- Where
- 1 siteIsrael
- Study dates
- Aug 2012to Aug 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: Pregnant women who address the emergency room, Ultrasound unit or foreign clinics.
Who may be able to join
- Pregnant women who address the emergency room, Ultrasound unit or foreign clinics in the second or third trimester.
Who cannot join
- Pregnant women in the first trimester Pregnant women who doesn't want to participate.
Trial locations and contacts
1 site in 1 country.
Alon Shrim, M.D. contact
About this study
The purpose of the study is to estimate the rate of risk factors for appearance of disease or fetal malformations in a population who turn to hospital "Hillel Yaffe" and examine whether there is a difference in the rate of early testing for diseases or birth defects in the fetus.
Understanding the population and its risk factors, will allow specific reference to these risk factors to lowering them to eventually reduce the rate of congenital malformations in this population.
Read the detailed description
Major defects prevalence in the general population is estimated at 5% of all live births. In cases where the fetus suffers from structural defect, chromosomal or genetic disease, prenatal diagnosis is an important scientific tool that allows reliable advice and better pregnancy outcomes.
Diseases and many embryonic defects can be detected early, including nervous system defects, heart defects, urinary tract defects, limb defects and more. Taking folic acid before pregnancy and during the first trimester reduces the incidence of some of these defects.
Aneuploidy and mainly trisomy 21,18,13, Monosomy X and aneuploid in sex chromosome is responsible for most of the chromosomal anomalies. Some of aneuploidy can be diagnosed by a combination of nuchal translucency (also associated with cardiac abnormalities) and maternal serum markers detection in the first trimester of pregnancy or a laboratory test in the second trimester. Ultrasound is also a tool for diagnosis of aneuploidity, which detecting abnormalities characteristic or "soft signs" who suspicious in chromosomal disorder.
Genetic tests is another diagnostic tool that suggested to general population and in individual cases adapted to genetic diseases that are known.
In 2008 about 75.5% of the population in Israel were Jews, 20.2% Arabs, and 4.3 were defined as "others". Approximately 45% of Arabs living in the northern region compared to 10% of the Jewish population. Congenital malformations were the leading cause of death in infants Arab and the second cause of death in Jewish infants.
In recent years the supply of screening before and during pregnancy has increased, but it is apparent that the rate of implementation of nuchal translucency, amniocentesis and therefore detection of disease are lower in Arab population, as well as the rates of taking folic acid. These differences between populations in carrying out tests that enable prevention and early detection of birth defects and neonatal genetic diseases also associated with differences in economic, religious and age of the woman.
In this work we try to know the population applying for medical services at Hillel Yaffe Hospital. Estimate the rate of risk factors for appearance of disease or fetal malformations in a population who turn to hospital "Hillel Yaffe" and examine whether there is a difference in the rate of early testing for diseases or birth defects in the fetus.
We hypothesize that a large percentage of the population who turn to Hillel Yaffe Hospital has risk factors for having a sick fetus and the Muslim population is in higher risk than the Jewish population.
Understanding the population and its risk factors, will allow specific reference to these risk factors to lowering them to eventually reduce the rate of congenital malformations in this population.
- Conditions
- Pregnancy, Pregnancy Complications
- Keywords
- Risk factors,, prenatal diagnosis,, fetal malformations
- Medical subject headings
- Pregnancy Complications, Congenital Abnormalities
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Aug 2012 (estimated)
- Study startAug 2012
- Primary completionSep 2012 (estimated)
- Study completionAug 2013 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Cross-sectional
- Enrolment
- 320 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hillel Yaffe Medical Center
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- yael yagur, student, Principal investigator, Technion, Israel Institute of TechnologyAlon Shrin, M.D., Study director, Ultrasound unit manager, obstetric and gynaecology, Hillel Yaffe
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01662596
- Sponsor's protocol ID
- 0044-12-HYMC
- Status last verified
- Aug 2012
- First submitted
- 7 Aug 2012
- Last updated
- 10 Aug 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 10 Aug 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Detection of Risk Factors for Fetal Anomalies in a Rural Hospital Population
- ClinicalTrials.gov ID
- NCT01662596
- Acronym / sponsor ID
- 0044-12-HYMC
- Conditions
- Pregnancy, Pregnancy Complications
- Keywords
- Risk factors,, prenatal diagnosis,, fetal malformations
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 320 participants (estimated)
- Lead sponsor
- Hillel Yaffe Medical CenterOther government
- Study start
- Aug 2012
- Primary completion
- Sep 2012 (estimated)
- Study completion
- Aug 2013 (estimated)
- First posted
- 10 Aug 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to estimate the rate of risk factors for appearance of disease or fetal malformations in a population who turn to hospital "Hillel Yaffe" and examine whether there is a difference in the rate of early testing for diseases or birth defects in the fetus.
Understanding the population and its risk factors, will allow specific reference to these risk factors to lowering them to eventually reduce the rate of congenital malformations in this population.
Detailed description
Major defects prevalence in the general population is estimated at 5% of all live births. In cases where the fetus suffers from structural defect, chromosomal or genetic disease, prenatal diagnosis is an important scientific tool that allows reliable advice and better pregnancy outcomes.
Diseases and many embryonic defects can be detected early, including nervous system defects, heart defects, urinary tract defects, limb defects and more. Taking folic acid before pregnancy and during the first trimester reduces the incidence of some of these defects.
Aneuploidy and mainly trisomy 21,18,13, Monosomy X and aneuploid in sex chromosome is responsible for most of the chromosomal anomalies. Some of aneuploidy can be diagnosed by a combination of nuchal translucency (also associated with cardiac abnormalities) and maternal serum markers detection in the first trimester of pregnancy or a laboratory test in the second trimester. Ultrasound is also a tool for diagnosis of aneuploidity, which detecting abnormalities characteristic or "soft signs" who suspicious in chromosomal disorder.
Genetic tests is another diagnostic tool that suggested to general population and in individual cases adapted to genetic diseases that are known.
In 2008 about 75.5% of the population in Israel were Jews, 20.2% Arabs, and 4.3 were defined as "others". Approximately 45% of Arabs living in the northern region compared to 10% of the Jewish population. Congenital malformations were the leading cause of death in infants Arab and the second cause of death in Jewish infants.
In recent years the supply of screening before and during pregnancy has increased, but it is apparent that the rate of implementation of nuchal translucency, amniocentesis and therefore detection of disease are lower in Arab population, as well as the rates of taking folic acid. These differences between populations in carrying out tests that enable prevention and early detection of birth defects and neonatal genetic diseases also associated with differences in economic, religious and age of the woman.
In this work we try to know the population applying for medical services at Hillel Yaffe Hospital. Estimate the rate of risk factors for appearance of disease or fetal malformations in a population who turn to hospital "Hillel Yaffe" and examine whether there is a difference in the rate of early testing for diseases or birth defects in the fetus.
We hypothesize that a large percentage of the population who turn to Hillel Yaffe Hospital has risk factors for having a sick fetus and the Muslim population is in higher risk than the Jewish population.
Understanding the population and its risk factors, will allow specific reference to these risk factors to lowering them to eventually reduce the rate of congenital malformations in this population.
Study design
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Pregnant women who address the emergency room, Ultrasound unit or foreign clinics.
Key inclusion criteria (1 listed)
- Pregnant women who address the emergency room, Ultrasound unit or foreign clinics in the second or third trimester.
Key exclusion criteria (1 listed)
- Pregnant women in the first trimester Pregnant women who doesn't want to participate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Aug 2012.
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alon Shrim, M.D. contact
yael yagur, student principal investigator
Technion, Israel Institute of Technology
Alon Shrin, M.D. study director
Ultrasound unit manager, obstetric and gynaecology, Hillel Yaffe
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pregnancy and Pregnancy Complications, run by Hillel Yaffe Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 Aug 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yael Yagur, student (972-52-3309429, yaelyagur@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Aug 2012.